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Abstract 
Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past 
few years. ICIs offer an alternative treatment strategy by exploiting the patients’ immune system, 
resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different 
tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular 
imaging, using single-photon emission computed tomography (SPECT) and positron emission 
tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell 
characteristics and might support patient selection or response evaluations for ICI therapies. In this 
review, recent studies with 18F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints 
and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but 
the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI 
therapy. 
Key words: molecular imaging; biomarkers; positron emitting tomography; immune checkpoint inhibitor; 
immunotherapy. 
Introduction 
Since the approval of ipilimumab by the Food 
and Drug Administration (FDA) and European 
Medicines Agency (EMA) in 2011, immune 
checkpoint inhibitors (ICIs) have substantially 
changed the field of oncology. Monoclonal antibody 
(mAb) based therapies targeting cytotoxic 
T-lymphocyte antigen 4 (CTLA-4), programmed cell 
death 1 (PD-1) or programmed cell death ligand 1 
(PD-L1) have improved patient survival across 
various tumor types (1-8). ICI therapies target the 
ability of cancer cells to evade the patient’s immune 
system through disruption of inhibitory ligand- 
receptor interactions. This allows effector T cells to 
recognize and eradicate tumor cells. Currently, seven 
ICIs have been approved for clinical use by the FDA 
and EMA. These are the anti-CTLA-4 antibody 
ipilimumab, the anti-PD1 antibodies nivolumab, 
pembrolizumab and cemiplimab, and the anti-PD-L1 
antibodies atezolizumab, avelumab and durvalumab. 
These antibodies are currently used to treat multiple 
tumor types including: melanoma, hepatocellular 
carcinoma, small-cell lung cancer, non-small-cell lung 
carcinoma (NSCLC), renal cell carcinoma, urothelial 
carcinoma, Hodgkin lymphoma, head and neck 
squamous cell carcinoma (HNSCC), Merkel cell 
carcinoma, gastric cancer, primary mediastinal large 
B-cell lymphoma and cervical cancer. Moreover, the 









tumor agnostic therapy for patients with 
microsatellite instability–high (MSI-H) or deficient 
DNA mismatch repair (dMMR) tumors. This list of 
indications has been steadily growing as research 
progresses. 
Despite this progress, a substantial group of 
patients does not respond to ICI therapy. A 
cross-sectional analysis of US patients with cancer 
eligible for ICI therapy for registered indications 
estimated a response rate of 12.46% in 2018 (9). This 
unfortunately means that even for registered 
indications, only a minority of patients gain long term 
survival benefit from ICI therapy. Even though ICIs 
are generally well tolerated, they can cause 
immune-related adverse events (irAE). Higher 
response rates have been reported when ICIs are 
combined, but this coincides with an increase and 
different kinetics of irAEs (10, 11). Therefore, there is a 
need for reliable predictive biomarkers to either select 
patients at baseline for ICI therapy or to evaluate 
treatment efficacy early during therapy. Identifying 
which patients will benefit from these therapies 
would greatly improve patient care. Several 
biomarkers have been studied for ICI therapy. 
Currently, PD-L1 expression measured using 
immunohistochemistry (IHC) and MSI-H and dMMR 
status measurement by IHC and polymerase- 
chain-reaction based assays are the only approved 
biomarkers for ICI therapy. However, the assay for 
PD-L1 expression is hampered by multiple variables 
involved in tumor tissue analyses, such as: sampling 
errors, spatial heterogeneity or temporal 
heterogeneity of tumor characteristics (12-14). 
Molecular imaging with single-photon emission 
computed tomography (SPECT) and positron 
emission tomography (PET), using specific 
radiopharmaceuticals, might potentially circumvent 
some of these issues. These techniques allow for 
non-invasive whole-body visualization of tumor and 
immune cell characteristics. Uptake of molecular 
imaging tracers can be quantified, and these 
measurements permit the technique to generate 
biomarkers. Since tumor characteristics, such as 
PD-L1 expression or tumor infiltrating lymphocyte 
numbers, can change over time, serial scans might 
provide information about dynamics of these aspects 
(13, 15).  
Extensive research is being conducted to study 
the feasibility of molecular imaging biomarkers for 
ICI therapy. Regarding biomarkers, we adhere in this 
review to the terminology and definitions as posed by 
the FDA-NIH Biomarker Working Group and 
O’Connor et al. (16, 17). An imaging biomarker is 
defined as “a spatially delineated biomarker derived 
from measurements made on an image” (16). 
Quantification of tracer uptake, expressed as 
standardized uptake values (SUV), and anatomical 
imaging measurements can both serve as a biomarker. 
In this review, recent advances in the development of 
molecular imaging biomarkers for ICI therapies with 
the focus on molecular imaging approaches in clinical 
development will be discussed.  
Search strategy 
PubMed was searched for relevant publications. 
Articles were selected when they were: published in 
peer reviewed journals, written in English and were 
available in full text. ClinicalTrials.gov was queried 
for relevant clinical trials investigating molecular 
imaging approaches for ICI therapies. The 2019 
conference abstracts of the American Society of 
Clinical Oncology (ASCO) and the American 
Association of Cancer Research (AACR) were 
searched for relevant new developments. These 
databases were searched up to May 2019. The 
following key words were used in the literature 
search: molecular, imaging, immunotherapy, 
checkpoint, inhibitor, immune, positron emitting 
tomography OR PET, single-photon emission 
computed tomography OR SPECT, programmed cell 
death protein 1 OR PD-1, programmed death-ligand 1 
OR PD-L1, cytotoxic T-lymphocyte-associated protein 
4 OR CTLA-4, lymphocyte, tumor, cancer, CD8, CD4, 
CD3. Specific search terms for isotopes included 
(zirconium OR Zr-89 OR 89Zr), (copper OR cu-64 OR 
64Cu), (fluorine OR F-18 OR 18F), (gallium OR Ga-68 
OR 68Ga), (iodine OR I-124 OR 124I), (yttrium OR y-86 
OR 86y), (carbon OR c-11 OR 11C), (technetium OR 
Tc-99m OR 99mTc).  
Response evaluation of ICIs  
Currently, the Response Evaluation Criteria in 
Solid Tumors (RECIST) version 1.1, for which the 
criteria were validated on a data warehouse, are used 
to determine response to chemotherapeutic drugs. 
These criteria are based on anatomical imaging 
measures (18). However, ICI therapy can result in 
temporary pseudo-progression. Therefore, the 
RECIST working group developed a guideline for 
data collection with a modified version of RECIST 
v1.1 for immune based therapeutics termed iRECIST 
(19). The major change being that in case of 
progression, while the patient’s condition is not 
deteriorating, the progression has to be confirmed a 
few weeks later to prove progressive disease during 
ICI. The data, collected using these guidelines, will be 
used to define the iRECIST criteria, once sufficient 
studies have been analyzed.  





Table 1. Studies with 18FDG-PET for tumor response evaluation of checkpoint inhibitor therapy 
Treatment Tumor type Number of 
patients 
Response criteria Imaging time points Summary of findings Reference 
Ipilimumab Melanoma 22 EORTC 18F-FDG-PET scan at 
baseline, after 2 cycles and 
after 4 cycles ipilimumab 
18F-FDG-PET/CT after 2 treatment cycles is predictive 
of final treatment outcome in patients with progressive 





Melanoma 27 Qualitative visual 
analysis 
18F-FDG-PET scan on 
treatment (median after 15.2 
months) 
Negative 18F-FDG-PET scans may hold negative 
predictive value for disease progression 
(21) 
 
Ipilimumab Melanoma 31 Fractal and 
multifractal analysis 
18F-FDG-PET scan at 
baseline, and after 2 and 4 
cycles ipilimumab 
In 20 out of 24 cases (83.3 %), results of the fractal and 








Melanoma 20 RECIST 1.1 and 
PERCIST  
18F-FDG-PET/CT at 4 weeks 
and at 4 months 
18F-FDG-PET/CT scans predict response with 100% 
sensitivity, 93% specificity and 95% accuracy  
(23) 
 
Nivolumab NSCLC 24 RECIST 1.1 versus 
PERCIST 
18F-FDG-PET scan at 
baseline and at 1 month 
Metabolic response (especially total lesion glycolysis) 




Checkpoint inhibitor NSCLC 27 Semi-quantitative 
analysis (SUVmax and 
SUVmean) 
18F-FDG-PET scan at 
baseline 
SUVmax ≤17.1 (sensitivity 88.9%) or a SUVmean ≤8.3 




Ipilimumab Melanoma 41 PERCIMT Baseline and after 4 cycles 
ipilimumab 
Four new 18F-FDG-avid lesions after 4 cycles 
ipilimumab is an indication of nonresponse  
(26) 
 
Ipilimumab Melanoma 41 PERCIMT versus 
EORTC 
Baseline and after 2 cycles 
ipilimumab 
PERCIMT more sensitive predictor of 





monotherapy or plus 
ipilimumab 
Melanoma 104 RECIST and EORTC Baseline and after 1 year After 1 year of therapy, 68% patients with a partial 
response on CT scan had a complete metabolic 
response on 18F-FDG PET scan  
(28) 
 
Nivolumab NSCLC 28 iPERCIST versus 
iRECIST 
Baseline, after 2 months, and 
when warranted after 3 
months 
Comparison of iPERCIST to iRECIST showed 
reclassification of 39% of patients with relevant 







43 Visual evaluation 
according to 
Deauville score and 
Lugano criteria 
Baseline, after 8 weeks and 
after 17 weeks 
No differences compared to the LYRIC criteria. 
Metabolic activity could be related to immune 
response as early as 8 weeks after start of treatment 
(30) 
Ipilimumab Melanoma 60 PERCIST Baseline and after 
completing ipilimumab 
treatment 
Tumor response according to PERCIST associated with 
OS. This association improved when using modified 
response criteria (imPERCIST) 
(31) 
 
Abbreviations: EORTC: European Organization for Research and Treatment of Cancer; iPERCIST: immune PET Response Criteria in Solid Tumors; iRECIST: immune 
Response Evaluation Criteria in Solid Tumors; OS: overall survival; PERCIMT: PET Response Evaluation Criteria for Immunotherapy; PERCIST: PET Response Criteria in 
Solid Tumors; RECIST: Response Evaluation Criteria in Solid Tumors; SUV: standardized uptake value. 
 
18F-FDG-PET imaging 
The 18F-fluorodeoxyglucose (18F-FDG)-PET scan, 
which visualizes increased cell metabolism with 
18F-radiolabeled glucose-like FDG in tumors and sites 
of inflammation, is the most frequently used type of 
PET scan in oncology. It is mainly used for staging of 
patients with cancer. 18F-FDG-PET is included in 
RECIST v1.1, but only to confirm progressive disease 
when indicated. Right now, not enough data is 
available to validate 18F-FDG-PET response criteria by 
the RECIST committee on a data warehouse. Several 
groups are exploring the use of 18F-FDG-PET scans for 
predicting response to ICI therapy (Table 1). Twelve 
studies, totaling 468 patients, evaluated the 
18F-FDG-PET in patients with melanoma, NSCLC and 
Hodgkin’s lymphoma (20-31). In these studies, 
metabolic responses are defined as a decrease in SUV 
in the tumor. The results do suggest an association 
between metabolic responses and clinical outcomes. 
However, multiple criteria were applied for 
18F-FDG-PET response evaluations, such as the 
EORTC criteria, PERCIST, PERCIMT, PECRIT and 
iPERCIST (24, 26, 29, 32, 33). Moreover, 18F-FDG-PET 
imaging was performed at different time points after 
starting ICI therapy, making comparisons difficult. 
For 18F-FDG-PET, to obtain a potential role for tumor 
response measurement during ICI therapy, 
standardized and harmonized procedures and 
analyses should be applied. Generating comparable 
data would allow for further analyses to define the 
role of 18F-FDG-PET in ICI therapies. Such a thorough 
analysis will be critical as changes in glucose 
metabolism can be caused by various cell types in the 
tumor microenvironment, including tumor cells, 
immune cells or stromal cells.  
Imaging of immune checkpoints 
PD-1:PD-L1 axis 
The PD-1 receptor is expressed by immune cells, 
mainly by activated T cells (34). It functions as an 
immune checkpoint. Binding to its ligand, PD-L1, 
results in inhibition of T cell activation. PD-L1 is 
expressed by various other immune cells, including 
dendritic cells, T cells and non-lymphoid 
parenchymal tissue cells (35). PD-L1 expression is 
upregulated upon cytokine release induced by T cell 





activation and an inflammatory environment. The 
PD-1:PD-L1 immune checkpoint is involved in 
maintaining immunological tolerance, and thus 
reducing auto-immunity and healthy tissue damage. 
Tumor cells expressing PD-L1, escape destruction by 
the immune system. Patients with high PD-L1 
expressing tumors, determined by IHC, tend to show 
better overall survival (OS) when treated with ICI 
compared to those with PD-L1 negative lesions. 
However, patients without PD-L1 tumor expression 
can respond to therapy (36-38). PD-L1 expression by 
tumor cells is dynamic and can be upregulated by ICI 
therapy and by inflammatory cytokines, such as 
interferon gamma (34, 39). Furthermore, tumor 
biopsies do not take into account the spatial 
heterogeneity of PD-L1 target expression, which can 
highly differ within and across metastases within one 
patient (15, 40-47).  
PD-1:PD-L1 imaging with full antibodies 
Full mAbs are large proteins, generally around 
150 kDa. Their weight and structure causes slow 
tissue distribution after intravenous administration 
and prevents filtration by the kidneys, resulting in an 
elimination half-life around 18-21 days (48). For 
imaging purposes, optimal PET imaging with full 
mAb tracers requires several days to allow the 
antibody to accumulate at the target location. 
Acquisition of the optimal PET images generally takes 
place 4-7 days after tracer injection. 
Two clinical studies have been published in 
which therapeutic anti-PD1 or anti-PD-L1 mAbs have 
been radiolabeled for PET imaging of the PD-1:PD-L1 
checkpoint. This approach can provide information 
about their tumor penetration and target engagement. 
One trial was performed with 10 mg of the PD-L1 
antibody atezolizumab radiolabeled with zirconium- 
89 (89Zr) and PET imaging on days 4 and 7 in patients 
with NSCLC, cancer of the urinary tract, and triple 
negative breast cancer prior to atezolizumab 
treatment (figure 1) (49). 89Zr-atezolizumab tumor 
uptake was positively associated with a response rate 
to atezolizumab treatment. Moreover, the geometric 
mean uptake of 89Zr-atezolizumab above or below 
median correlated to progression free survival (PFS) 
and OS. For individual lesions, higher 
89Zr-atezolizumab tracer uptake is associated with 
tumor size reduction over time. In contrast, PD-L1 
expression in tumor biopsies, obtained 7 days after 
tracer injection and immediately after the last PET 
scan, did not correlate with response to therapy. 
Tracer uptake was also seen in lymphoid tissues such 
as normal lymph nodes, tonsils and the spleen. Since 
PD-1:PD-L1 inhibitors induce a systemic immune 
response with effects throughout the body, tracer 
uptake measured with PET in normal tissues might 
also serve as a proxy for evaluation of activation of the 
immune system. Uptake of the tracer was also seen in 
sites of inflammation, including a sinusitis and a knee 
bursitis. Another study reported high 89Zr- 
atezolizumab uptake in a mouse bearing a tumor graft 
model of a patient with metastatic clear cell renal cell 
carcinoma. This patient later appeared to have a 
durable response to nivolumab treatment (50).  
 
 
Figure 1. Comparison of 18F-FDG-PET and 89Zr-atezolizumab-PET 
imaging. Maximum intensity projections of 18F-FDG-PET, 1 h after tracer injection 
(A) and 89Zr-atezolizumab-PET, 7 days after tracer injection (B) of a 53 year old 
woman diagnosed with NSCLC. Both imaging modalities show uptake in multiple 
intra-pulmonary metastases. The 18F-FDG-PET scan shows physiological high uptake 
in the brain and excretion via the kidneys. At the moment of this scan the patient had 
a post-renal obstruction due to a kidney stone. The 89Zr-atezolizumab-PET scan 
shows high uptake in the spleen (red arrow). The 18F-FDG-PET scan was performed 
46 days prior to the 89Zr-atezolizumab-PET scan. Both scans were scaled equally 
(0-8). 
 
In another study a PD-1 antibody, namely 2 mg 
nivolumab was radiolabeled with 89Zr and PET 
imaging was performed 7 days after tracer injection in 
13 patients with NSCLC prior to nivolumab treatment 
(51). Uptake of 89Zr-nivolumab was analyzed for 21 
tumor lesions: uptake was higher in the 7 lesions that 
showed a reduction in size of ≥30% at 12 weeks after 
start with nivolumab treatment. 89Zr-nivolumab 
uptake correlated with PD-1 expression by tumor- 
infiltrating immune cells assessed by IHC, in fresh 
baseline tumor biopsies or archival tissue. Also, 
spleen tracer uptake was seen with a SUV of 5.8, 
which is much lower than the spleen uptake seen with 
89Zr-atezolizumab (49). In the 89Zr-nivolumab study, 
five out of 13 patients responded to the therapy: the 
study provides a rationale for evaluation of 
89Zr-nivolumab in a larger cohort to evaluate its 
potential as a tool for response prediction.  
All currently approved PD-1:PD-L1 targeting 
antibodies have been radiolabeled with 89Zr (49, 
51-54). This radionuclide with radioactive half-life 





(78.4 hours) suits the long half-life of the antibodies 
and their tendency to slowly distribute in the body. 
Radiolabeled tracers of registered anti-PD-L1 mAbs, 
such as 89Zr-avelumab (NCT03514719), 89Zr- 
durvalumab (NCT03610061, NCT03829007) and 
89Zr-atezolizumab (NCT02453984, NCT03850028) are 
currently investigated in clinical trials. Most of these 
studies perform PET imaging prior to ICI therapy to 
evaluate tracer uptake in the tumor lesions as a 
predictive biomarker. Another multicenter trial in 
patients with thoracic malignancies recently started 
with 89Zr-labeled REGN3504, a non-registered 
anti-PD-L1 antibody (NCT03746704). 89Zr- 
atezolizumab PET imaging is also performed serially 
during atezolizumab therapy to evaluate tumor 
saturation by atezolizumab (NCT02453984). 
Two trials with the PD-1 antibody 89Zr- 
pembrolizumab are ongoing (NCT02760225, 
NCT03065764), both performing PET imaging before 
starting ICI therapy.  
PD-1:PD-L1 imaging with small 
molecules and antibody fragments 
Smaller molecules have been engineered for 
imaging of PD-1 and PD-L1 (55-57). These agents are 
in general not designed to induce a therapeutic effect, 
but to enable early imaging. An exception is the PET 
tracer 89Zr-KN035 (55). KN035, a 79.6 kDa domain 
antibody targeting PD-L1, is evaluated in several 
clinical trials for its therapeutic potential. The 
89Zr-labeled domain antibody is studied to evaluate 
the biodistribution and lesion uptake of the tracer in 
patients with PD-L1 positive advanced solid tumors 
(NCT03638804). 
In the above-mentioned clinical trial with 
89Zr-nivolumab (51), they also studied a radiolabeled 
anti-PD-L1 adnectin (18F-BMS-986192) with a 
molecular weight around 10 kDa (58, 59). Fluorine-18 
(18F) with a radioactive half-life of 110 minutes 
resembles the elimination half-life of small molecules 
like adnectins. PET acquisition was performed 60 
minutes after 18F-BMS-986192 injection. 
18F-BMS-986192 uptake was higher in the three 
patients with PD-L1 expression of ≥50% determined 
by IHC. However, higher tracer uptake did not 
correlate with response to nivolumab treatment in this 
small cohort.  
A single domain antibody (sdAb) NM-01 with a 
molecular weight of ~15 kDa, which binds human 
PD-L1 was labeled with technetium-99m (99mTc) for 
SPECT imaging in patients with NSCLC prior to 
anti-PD-L1 antibody treatment (59). In an early 
analysis of the first 16 patients, the tracer showed 
heterogeneous tumor uptake between patients, 
between metastases and within tumors. No data is 
reported on correlation with uptake of the tracer and 
outcome of therapy. Besides uptake in the spleen and 
bone marrow, the authors do not report on specific 
uptake of this PD-L1 tracer in other normal lymphoid 
tissues. The trial is ongoing and aims to recruit 50 
patients (NCT02978196).  
Compared to the full antibodies agents 
89Zr-atezolizumab (49) and 89Zr-nivolumab (51), 
clearance of 99mTc-NM-01 is faster, resulting in mean 
tumor:bloodpool ratios of 1.79 (1.24-2.3) at 1 hour 
after injection and 2.33 (1.24-3.53) at 2 hours after 
injection. 89Zr-atezoluzimab PET showed the highest 
tumor:bloodpool ratio around 5.0 on day 7. Overall, 
89Zr-atezolizumab uptake in tumors had geometric 
mean SUVmax 10.4. Imaging of 89Zr-nivolumab at 7 
days after tracer injection yielded a mean SUVpeak of 
6.4 in responding lesions versus 3.9 in 
non-responding lesions; uptake of 18F-BMS986192 1 
hour after injection showed similar uptake values. 
However, no information about contrast to 
background tissue and bloodpool are provided, 
making it difficult to interpret the imaging results and 
uptake values of the tracers. 
The peptide WL12 (14–amino acid circular 
peptide), engineered to bind PD-L1 with high affinity, 
was radiolabeled with copper-64 (64Cu) to allow for 
PET imaging (60). Although only tested in mouse 
models, WL12 shows the potential for imaging with 
small molecules. The binding interface of WL12 to 
PD-L1 overlaps with that of its natural receptor PD-1 
and all registered PD-L1 antibodies. Therefore, the 
authors suggest that it may be used to evaluate 
unoccupied PD-L1, providing information on 
drug-target engagement for prediction of ICI therapy 
efficacy. Performance of the tracer in mouse models 
did indeed demonstrate reduction of 64Cu-WL12 
uptake in tumors after atezolizumab treatment. This 
outcome was consistent in tumors with different 
expression levels of PD-L1, and dose and time 
dependent changes could be quantified. Analyses of 
tissue penetration of a mAb may be of interest. In a 
study with 89Zr-trastuzumab, a mAb against human 
epithelial growth factor 2 (HER2), 29% of the patients 
with tumors expressing HER2 expression by IHC 
showed no uptake of 89Zr-trastuzumab in their 
tumors (61). Apparently, penetration of a drug into 
tumor tissue does not solely rely on target presence. 
An ongoing 89Zr-atezolizumab study (NCT02453984) 
addresses this issue by repeating imaging during 
atezolizumab treatment. Head-to-head comparisons 
of the imaging performance of mAbs versus smaller 
PD-L1 binding moieties are still lacking. 
Reported results on quantification of tracer 
uptake differ between all reported tracers targeting 
the PD-1:PD-L1 axis. Overall, 89Zr-atezolizumab 





showed the highest SUV in tumor tissue compared to 
the other clinically evaluated tracers 89Zr-nivolumab, 
18F-BMS986192 and 99mTc-NM-01. 
Imaging of CTLA-4  
Ipilimumab, which blocks checkpoint molecule 
CTLA-4, was the first ICI in the clinic in 2011. CTLA-4 
is expressed by activated T cells and regulatory T cells 
(Tregs); expression levels are upregulated after binding 
of the T cell receptor with antigen on antigen 
presenting cells (34). Ligands for CTLA-4 are B7-1 and 
B7-2 on antigen presenting cells, for which CTLA-4 
competes with the stimulatory molecule CD28 on T 
cells. Engagement of the ligands with CTLA-4 causes 
an inhibitory signal for T cell activation, due to its 
competition with CD28 and prevention of ligand 
binding to CD28.  
Currently one clinical trial (NCT03313323) is 
investigating CTLA-4 imaging with 89Zr-ipilimumab 
as a predictive biomarker for ipilimumab therapy. 
89Zr-ipilimumab uptake is quantified upfront and 
early during treatment with ipilimumab, with the 
idea that patients who do not benefit from 
ipilimumab treatment may have lower levels of the 
drug in tumor tissues.  
In immunocompetent mice, an anti-mouse 
64Cu-DOTA-anti-CTLA-4 mAb was used to visualize 
CTLA-4 levels in tissues (62). The mouse tumor cell 
line expressed little CTLA-4, but when growth was 
induced, these tumors showed high tracer uptake on 
the 64Cu-DOTA-anti-CTLA-4 PET scan, which 
correlated with higher influx of tumor infiltrating 
lymphocytes. In contrast, little uptake of the tracer 
was seen in tumors in immunodeficient mice.  
In another study CTLA-4 PET imaging was 
performed in a humanized mouse model (63). 
64Cu-NOTA-ipilimumab and 64Cu-NOTA- 
ipilimumab-F(ab’)2, a full antibody and an antibody 
fragment, localized CTLA-4+ engrafted human 
peripheral blood lymphocytes. These preclinical 
results suggest that it is feasible to perform PET 
imaging with anti-CTLA-4 tracers to visualize 
CTLA-4. 
Upcoming targets in checkpoint 
inhibition 
As developments proceed, more checkpoint 
molecules are becoming subject of research, including 
lymphocyte activation gene 3 (LAG-3), T-cell 
immunoglobulin and mucin-domain containing-3 
(TIM3), T cell immunoreceptor with Ig and ITIM 
domains (TIGIT) and V-domain Ig suppressor of T 
cell activation (VISTA) (34, 64, 65). Currently, 
anti-LAG-3 antibodies are most extensively studied, 
with 50 ongoing trials registered at ClinicalTrials.gov. 
LAG-3, a checkpoint molecule that is upregulated on 
activated T cells, is considered to be a marker for T cell 
exhaustion. LAG-3 binds to major histocompatibility 
complex-II (MHC-II), thus preventing binding of the T 
cell receptor to MHC-II (66). LAG-3 PET imaging has 
been performed in mice. 89Zr-REGN3767 visualized 
LAG-3 expressing intratumoral T cells after 
co-implantation with human lymphoma cells and 
human peripheral blood mononuclear cells (67). 
89Zr-LAG-3 PET is currently studied in patients with 
NSCLC and HNSCC prior to anti-LAG-3 therapy 
(NCT03780725).  
Not only inhibitory immune checkpoints are 
being investigated. Costimulatory checkpoint 
molecules, such as OX40 (CD134), inducible T cell 
costimulator (ICOS, CD278), glucocorticoid-induced 
TNFR-related protein (GITR), 4-1BB (CD137), CD40 
and CD27 have been identified as potential 
therapeutic targets. For OX40 (68) and CD40 (69), 
radiotracers targeting these cell surface proteins have 
been developed.  
Imaging of T cells 
Immunotherapy can potentiate the T cell 
mediated immune response against tumor cells. 
Therefore, molecular imaging of T cells has great 
potential for the evaluation of new and current 
therapies. Visualizing T cells might allow us to 
evaluate the anti-tumor immune response early and 
could potentially support adaptations of the 
treatment regimen.  
As the immune checkpoint molecules CTLA-4, 
PD-1 and PD-L1 are present on T cells, imaging with 
tracers targeting the checkpoint interactions generates 
information on presence, activation and migration of 
T cells. Moreover, imaging of T cells can also be 
performed with tracers against T cell specific targets, 
independent of checkpoint molecules. Cluster of 
differentiation 8 positive (CD8+) T cells are generally 
considered to be the main effector cells involved in the 
immune response against tumor cells. Several tracers 
have been developed to visualize CD8+ T cells. 
Radiolabeled antibody constructs can detect changes 
in tumor infiltrating lymphocytes following ICI 
therapy in mice (70-73). Two CD8 PET tracers are 
studied clinically: a phase I trial using a zirconium 
labeled mini-body construct (⁸⁹Zr-Df-IAB22M2C) has 
been completed (NCT03107663) and is now evaluated 
in a phase II trial (NCT03802123). The preliminary 
results of the phase I trial showed no tracer related 
adverse effects, cytokine release syndrome or blood 
test abnormalities. The anti-CD8 tracer accumulated 
in CD8-rich tissues, such as the spleen, bone marrow 
and lymph nodes. Tracer uptake by the tumor was 
variable and seen in 10 of the 15 patients (74). Another 





zirconium labeled anti-CD8 imaging agent 
ZED88082A is currently studied in patients that 
receive ICIs (NCT04029181).  
Another approach is the use of radiolabeled 
interleukin-2 (IL2) for lymphocyte imaging. The high 
affinity IL2 receptor, which consists of three 
subdomains (CD25, CD122 and CD132) is highly 
expressed by several lymphocyte subtypes, such as 
Tregs and activated T cells. The low affinity IL2 
receptor, which consists of two subdomains (CD122 
and CD132) is found on naive T cells, memory T cells 
and natural killer cells (75). A first proof of concept 
study was performed in five patients with metastatic 
melanoma using 99mTc labeled interleukin-2 
(99mTc-IL2) (76). Patients were scanned at baseline and 
12 weeks after starting treatment. In two out of three 
patients that underwent an on-treatment 99mTc-IL2 
PET scan, a lower total SUVmax was seen in the tumor 
lesions after treatment, while one patient had an 
increase in total SUVmax. A 18F labeled IL2 tracer is 
being evaluated in melanoma patients 
(NCT02922283). Patients are scanned at baseline and 
during ICI therapy to determine whether changes in 
tumor tracer uptake correlate with response to ICI 
therapy.  
18F labeled 9-β-d-arabinofuranosylguanine 
([18F]F-AraG) is also investigated as a PET tracer for T 
cell imaging in cancer patients. [18F]F-AraG is a 
positron-emitting guanosine analog that selectively 
accumulates in T cells. [18F]F-AraG can be 
phosphorylated by cytoplasmic deoxycytidine kinase 
and deoxyguanosine kinase and is subsequently 
trapped intracellularly (77, 78). This tracer is 
evaluated in stage I-IIIa NSCLC patients receiving 
neoadjuvant pembrolizumab with or without 
radiotherapy (NCT03311672). A single [18F]F-AraG 
PET scan is performed after 2 cycles pembrolizumab. 
Results will be compared to CD3+ T cell numbers 
present in the resection specimens.  
It is a challenge for T cell imaging to determine 
the optimal imaging time point to capture the T cell 
influx, as the time it takes to detect major T cell 
accumulation in the tumor microenvironment 
following ICI therapy is not yet precisely known. 
Lymphocyte activation, proliferation and functional 
differentiation can occur in a matter of days following 
viral infection (79). Whether this also applies for ICI 
therapy in cancer is unknown. T cell influx early 
during treatment has been investigated by obtaining 
early on-treatment biopsy samples and by studying 
resection specimen in neoadjuvant ICI therapy studies 
after treatment (Table 2). This data suggests that an 
increase in T cell numbers already occurs within a few 
weeks after the start of treatment (80-86). T cell 
imaging in this timeframe could provide a 
non-invasive way to visualize T cell dynamics after 
only one or two doses of ICI therapy.  
Another challenge for T cell imaging is the 
complexity of the human immune system, which 
consists, among others, of many lymphocyte 
subgroups which play different roles in the immune 
response. Some of these subgroups are 
pro-inflammatory or effector cells. Other subgroups, 
such as Tregs are anti-inflammatory and have been 
associated with worse OS and resistance to therapy 
(87, 88). Unfortunately, the abovementioned 
PET-tracers do not specifically target one uniform 
subgroup of T cells. The targets of these tracers can be 
expressed by both effector T cells as well as 
anti-inflammatory T cell subsets. At the same time, 
these tracers do not visualize all effector- or 
anti-inflammatory T cell subsets. For example, a tracer 
directed against CD8 only shows the CD8-mediated 
immune response. However, multiple different 
effector T cells have been implicated to play a role in 
the anti-tumor immune response. Some natural killer 
cells and γδ T cells do not express CD8 and therefore 
this part of the anti-tumor immune response might be 
overlooked during CD8 imaging (89, 90). 
Imaging of other immune components of 
the tumor microenvironment 
Understandably, most effort is focused on 
imaging of effector T cells to monitor the efficacy of 
immunotherapies. However, imaging of other 
immune cells might also offer valuable information 
regarding the dynamic tumor microenvironment. 
Besides effector immune cells, there are several 
immune cell types present in the tumor 
microenvironment, such as Tregs, tumor associated 
macrophages (TAMs) and myeloid-derived 
suppressor cells (MDSCs) (91). These cells play a key 
role in preserving the immunosuppressive state of the 
tumor microenvironment. To better understand the 
underlying mechanisms of resistance to ICI therapies, 
these cells types are of interest. Furthermore, a small 
subset of patients experiences early tumor 
progression after starting ICI therapy (92, 93). It is 
hypothesized that mechanisms associated with 
resistance to ICI therapy could be involved in 
hyperprogressive disease (93). This might be due to a 
shift towards a more immunosuppressive tumor 
microenvironment by proliferation or modulation of 
immunosuppressive cells, such as Tregs, M2 TAMs or 
MDSCs (94-96). Visualizing these 
immunosuppressive cells might be useful to 
distinguish pseudo-progression from 
hyperprogressive disease. 





Table 2. Changes in tumor infiltrating lymphocytes following ICI therapy in serial tumor tissues measured immunohistochemically 
Setting Treatment Tumor type Number of 
patients 
Sampling time points Summary of findings Reference 
Neoadjuvant 2 cycles nivolumab 3 
mg/kg body weight 
NSCLC 21 Baseline and tumor resection 
after 4 weeks 
Major pathological response in 45% of resected 
tumors 
(80) 
Neoadjuvant 2 cycles ipilimumab + 
nivolumab 
Melanoma 10 Baseline and tumor resection 
after 6 weeks 
Pathological response in 70% of biopsies (81) 
Neoadjuvant 1 cycle pembrolizumab Melanoma 27 Baseline and tumor resection 
after 3 weeks 
Complete or major pathologic response in 30% of 
patients. Increase in CD8 positive T cell numbers 




CTLA-4 blockade and/or 
PD-1 blockade 
Melanoma 53 Baseline and early on 
treatment (after 2-3 doses) 
Increase in CD8+ T cells  (83) 
On-treatment 
biopsy 
Pembrolizumab Melanoma 46 - Baseline 
- 20-60 days 
- 80-120 days 
- 120 days 
Increase in CD8 T cell density (cells/mm2) in 




Pembrolizumab Melanoma 53 Baseline and on treatment 
(median 74 days) 
Increase in T cell frequency. Increase in CD8+ 





Anti-PD1 therapy Melanoma 13 Baseline and early on 
treatment (14 days) 
Significant expansion of CD8+ cells early during 
treatment. Higher CD8 T cell numbers were seen in 
responders 
(86) 
Abbreviations: CD8: cluster of differentiation 8; CTLA-4: cytotoxic T lymphocyte antigen 4; NSCLC: non-small-cell lung carcinoma; PD-1, programmed cell death 1; Treg: 
regulatory T cell. 
 
At this moment, no Treg specific molecular 
imaging tracers are available. However, there are 
tracers that target both Tregs as well as other immune 
cell subgroups. Tregs are generally characterized as 
CD4+ CD25+ FoxP3+ T cells. Radiolabeled anti-CD4 
antibody constructs have been developed and are 
currently investigated for future application in the 
clinic (97, 98). Furthermore, Tregs constitutively 
express high levels of the IL2 receptor (75). Therefore, 
IL2 imaging might have a potential role in Treg 
imaging. Future studies will have to determine 
whether these tracers are effective at imaging Tregs and 
whether this holds any diagnostic value for 
visualizing resistance to therapy or the evaluation of 
tumor progression. Multiple PET and SPECT tracers 
have been developed for imaging of macrophages (99, 
100). These tracers are already being studied in 
diseases such as auto-immune diseases, 
atherosclerosis and cancer. However, imaging of 
macrophages has not yet been investigated for ICI 
therapies. MDSC imaging has been performed using 
99mTc‐anti‐CD11b SPECT imaging in a murine colon 
tumor model. Tracer uptake was seen in the tumor, 
spleen and bone marrow (101). 
Not only immune cells can be visualized using 
molecular imaging. Cytokines also play an important 
role in the dynamics of the tumor microenvironment. 
Transforming growth factor beta (TGF-β) causes 
exclusion of T cells from the tumor 
microenvironment. This is associated with poor 
prognosis in cancer, and resistance to PD-L1 and PD-1 
inhibitors. (102, 103). Currently, several trials are 
conducted with TGF-β inhibitors, some in 
combination with ICI, as preclinical findings have 
shown an increase in effector T cells in the tumor 
(103). PET imaging of TGF-β with the 89Zr-labeled 
antibody fresolimumab in patients with recurrent 
glioblastoma showed high tracer uptake in the tumor. 
This tumor type is known for high expression of 
TGF-β and its receptors (104). 89Zr-fresolimumab or 
other tracers visualizing TGF-β may enlighten 
resistance mechanisms to ICI therapy. 
Discussion 
The developments in ICI therapies have resulted 
in remarkable tumor responses and improvements in 
patient survival. An effective immune response 
induced by ICI therapy is the result of an interplay 
between the antibody targeting checkpoint molecules, 
the tumor cells, and the patient’s immune system. 
Molecular imaging has the potential to provide 
measurable imaging biomarkers that may predict 
effects of these therapies. Furthermore, radiolabeling 
of therapeutic mAbs informs researchers about the 
pharmacokinetic properties of these drugs.  
Translating preclinical findings from animal 
tumor models to clinical results is challenging. A 
realistic representation of a human immunological 
response requires not only a human(-ized) tumor 
model with a human target, i.e. with expression of 
human PD-L1, but also human variants of all the 
co-players attributing to an effective cancer immune 
response (105). Moreover, most preclinical mouse 
studies are done in mice aged 6-8 weeks, whereas 
patients usually develop cancer at an older age. This 
could be relevant as the immune system and 
lymphoid system are subject to change as people get 
older (106).  
The clinical studies discussed in this review are 
exploratory studies and provide only a glimpse of the 
tracer’s potential value. The major challenge lying 
ahead is implementing these imaging approaches in 





patient care. This requires harmonization of 
procedures and proper validation in larger cohorts. 
Data sharing and collaboration will truly benefit this 
process and reduce costs (107). However, it is a 
challenge worth facing as the approaches discussed in 
this review show great potential to provide insight in 
the ICI mediated anti-tumor immune response. 
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